Security
Damora Therapeutics, Inc. Ordinary Shares · DMRA
DMRANASDAQCommon stockCurrentCIK 1800315Updated Nov 6, 2026
Name history
Galecto, Inc. · through Mar 10, 2026Galecto Inc. · through Oct 28, 2020
DMRA price & chart
Loading TradingView…
NASDAQ:DMRA on TradingView ↗About the company
Damora Therapeutics is an innovative biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. We are advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is significant medical need for disease-modifying treatments. With multiple programs with best-in-class potential on track to enter clinical development in 2026, our goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. For more information, visit www.damoratx.com or follow us on LinkedIn.
In the news
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 10,736,000Source | 23,376,000Source | 543,636,000Source | 13,691,000Source | 27,297,000Source | 535,442,000Source | 15,365,000Source | 32,477,000Source | 260,527,000Source | 17,132,000Source | 38,227,000Source | 73,188,000Source |
| Property, Plant and Equipment, NetUSD | 41,000Source | 62,000Source | — | 47,000Source | 67,000Source | — | 52,000Source | 73,000Source | 36,000Source | 57,000Source | 78,000Source | 357,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 7,606,000Source | 19,678,000Source | 540,515,000Source | 10,211,000Source | 22,862,000Source | 532,899,000Source | 11,939,000Source | 21,091,000Source | 257,624,000Source | 14,175,000Source | 21,465,000Source | 32,786,000Source |
| Assets, CurrentUSD | 9,786,000Source | 21,178,000Source | 543,588,000Source | 13,027,000Source | 25,168,000Source | 535,408,000Source | 14,923,000Source | 30,541,000Source | 260,423,000Source | 16,839,000Source | 36,774,000Source | 63,910,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,180,000Source | 1,500,000Source | 3,073,000Source | 2,816,000Source | 2,306,000Source | 2,509,000Source | 2,984,000Source | 3,370,000Source | 2,799,000Source | 2,664,000Source | 3,623,000Source | 3,686,000Source |
| Operating Lease, Right-of-Use AssetUSD | 72,000Source | 32,000Source | — | 75,000Source | 76,000Source | — | 73,000Source | 152,000Source | 68,000Source | 73,000Source | 247,000Source | 810,000Source |
| Other Assets, NoncurrentUSD | 837,000Source | 2,104,000Source | 48,000Source | 542,000Source | 1,986,000Source | 34,000Source | 317,000Source | 1,711,000Source | 0Source | 163,000Source | 1,128,000Source | 2,279,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 2,729,000Source | 2,441,000Source | 27,577,000Source | 2,738,000Source | 3,709,000Source | 23,839,000Source | 1,656,000Source | 4,318,000Source | 20,147,000Source | 1,301,000Source | 5,896,000Source | 11,435,000Source |
| Stockholders’ equity: | ||||||||||||
| Additional Paid in CapitalUSD | 292,470,000Source | 291,053,000Source | 931,649,000Source | 292,297,000Source | 290,291,000Source | 893,542,000Source | 292,106,000Source | 289,395,000Source | 310,688,000Source | 291,898,000Source | 288,036,000Source | 279,733,000Source |
| Retained Earnings (Accumulated Deficit)USD | -286,627,000Source | -270,783,000Source | -546,320,000Source | -283,494,000Source | -266,900,000Source | -515,146,000Source | -280,057,000Source | -261,562,000Source | -487,363,000Source | -277,524,000Source | -256,085,000Source | -217,736,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 823,000Source | 665,000Source | 732,000Source | 809,000Source | 197,000Source | 754,000Source | 300,000Source | 326,000Source | 802,000Source | 97,000Source | 380,000Source | -244,000Source |
| Stockholders' Equity Attributable to ParentUSD | 8,007,000Source | 20,935,000Source | 516,059,000Source | 10,953,000Source | 23,588,000Source | 511,603,000Source | 13,709,000Source | 28,159,000Source | 240,380,000Source | 15,831,000Source | 32,331,000Source | 61,753,000Source |
| Liabilities and EquityUSD | 10,736,000Source | 23,376,000Source | 543,636,000Source | 13,691,000Source | 27,297,000Source | 535,442,000Source | 15,365,000Source | 32,477,000Source | 260,527,000Source | 17,132,000Source | 38,227,000Source | 73,188,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 2,623,000Source | 2,441,000Source | 27,550,000Source | 2,629,000Source | 3,709,000Source | 23,812,000Source | 1,551,000Source | 4,318,000Source | 20,066,000Source | 1,197,000Source | 5,830,000Source | 11,107,000Source |
| Operating Lease, Liability, CurrentUSD | 15,000Source | 32,000Source | — | 15,000Source | 77,000Source | — | 13,000Source | 155,000Source | 15,000Source | 12,000Source | 183,000Source | 476,000Source |
| Accounts Payable, CurrentUSD | 520,000Source | 503,000Source | 3,482,000Source | 756,000Source | 724,000Source | 819,000Source | 354,000Source | 1,665,000Source | 444,000Source | 377,000Source | 1,702,000Source | 3,350,000Source |
| Operating Lease, Liability, NoncurrentUSD | 57,000Source | — | — | 60,000Source | — | — | 60,000Source | — | 53,000Source | 61,000Source | 66,000Source | 328,000Source |
| Other Liabilities, NoncurrentUSD | 49,000Source | — | 27,000Source | 49,000Source | — | 27,000Source | 45,000Source | — | 28,000Source | 43,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 2,103,000Source | 1,938,000Source | 8,879,000Source | 1,873,000Source | 2,985,000Source | 5,997,000Source | 2,401,000Source | 2,653,000Source | 2,401,000Source | 820,000Source | 4,128,000Source | 7,757,000Source |
| Common Stock, Value, Issued | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -3,100,000Source | -3,900,000Source | -31,200,000Source | -3,400,000Source | -27,783,000Source | -2,533,000Source | -209,839,000Source | -21,439,000Source | -38,349,000Source | -61,624,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 3,134,000Source | 179,000Source | 998,000Source | 3,239,000Source | 5,427,000Source | 5,571,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 375,000Source | -23,000Source | 51,000Source | -1,325,000Source | -1,648,000Source | 1,819,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -20,598,000Source | -2,439,000Source | -6,726,000Source | -18,623,000Source | -36,911,000Source | -42,932,000Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | 17,374,000Source | — | — | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | -17,374,000Source | 11,650,000Source | 22,330,000Source | 12,384,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | — | — | 196,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 295,921,000Source | — | 266,844,000Source | — | 2,876,000Source | 507,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 7,606,000Source | 19,678,000Source | 540,515,000Source | 10,211,000Source | 532,899,000Source | 11,939,000Source | 257,624,000Source | 14,175,000Source | 21,465,000Source | 32,786,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | 2,000Source | 5,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -48,000Source | 203,000Source | 705,000Source | -317,000Source | 384,000Source | 264,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 164,000Source | 681,000Source | 10,687,000Source | 172,000Source | 8,118,000Source | 179,000Source | 998,000Source | 3,239,000Source | 5,427,000Source | 5,571,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | — | — |
| DepreciationUSD | — | — | 6,000Source | 6,000Source | — | — | 5,000Source | 5,000Source | 22,000Source | 21,000Source | 269,000Source | 42,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -19,000Source | -182,000Source | 16,000Source | -62,000Source | 0Source | -6,000Source | -84,000Source | 18,000Source | -197,000Source | -1,069,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | — | 64,000Source | — |
| General and Administrative ExpenseUSD | — | — | 1,740,000Source | 2,747,000Source | 9,454,000Source | 1,956,000Source | 7,034,000Source | 1,921,000Source | 9,685,000Source | 10,499,000Source | 12,687,000Source | 13,001,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 7,000Source | 255,000Source | 4,000Source | 42,000Source | 2,000Source | 50,000Source | 41,000Source | 0Source | 0Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | — | — | — | — | — | — | — | — | 231,000Source | -259,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,133,000Source | -3,883,000Source | -31,174,000Source | -3,437,000Source | -27,783,000Source | -2,533,000Source | -209,839,000Source | -21,439,000Source | -38,349,000Source | -61,624,000Source |
| Nonoperating Income (Expense)USD | — | — | 23,000Source | -36,000Source | 4,075,000Source | -12,000Source | 3,070,000Source | 68,000Source | 1,083,000Source | 862,000Source | 1,556,000Source | -417,000Source |
| Operating ExpensesUSD | — | — | 3,156,000Source | 3,840,000Source | 34,994,000Source | 3,421,000Source | 30,811,000Source | 2,599,000Source | 210,872,000Source | 22,260,000Source | 39,905,000Source | 61,207,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 2,876,000Source | 507,000Source |
| Restructuring CostsUSD | — | — | — | — | — | — | — | — | 0Source | 968,000Source | 3,448,000Source | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -3,156,000Source | -3,840,000Source | -34,994,000Source | -3,421,000Source | -30,811,000Source | -2,599,000Source | -210,872,000Source | -22,260,000Source | -39,905,000Source | -61,207,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -3,133,000Source | -3,876,000Source | -30,919,000Source | -3,433,000Source | -27,741,000Source | -2,531,000Source | -209,789,000Source | -21,398,000Source | -38,349,000Source | -61,624,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 7,000Source | 255,000Source | 4,000Source | 42,000Source | 2,000Source | 50,000Source | 41,000Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,133,000Source | -3,883,000Source | -31,174,000Source | -3,437,000Source | -27,783,000Source | -2,533,000Source | -209,839,000Source | -21,439,000Source | -38,349,000Source | -61,624,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -2.36Source | -3.39Source | -0.39Source | -2.6Source | -0.62Source | -1.92Source | 3.98Source | -18.53Source | -1.44Source | -2.43Source |
| Earnings Per Share, DilutedUSD per share | — | — | -2.36Source | -3.39Source | -0.39Source | -2.6Source | -0.62Source | -1.92Source | 3.98Source | -18.53Source | -1.44Source | -2.43Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 1,327,039Source | 1,144,978Source | 61,117,057Source | 1,322,553Source | 34,299,182Source | 1,322,011Source | 1,363,005Source | 1,157,149Source | 26,571,783Source | 25,409,123Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 1,327,039Source | 1,144,978Source | 61,117,057Source | 1,322,553Source | 34,299,182Source | 1,322,011Source | 1,363,005Source | 1,157,149Source | 26,571,783Source | 25,409,123Source |
| Additional Financial Items | ||||||||||||
| Common Stock, Dividends, Per Share, DeclaredUSD per share | — | — | — | — | — | — | 0Source | — | 0Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -19,000Source | -182,000Source | 16,000Source | -62,000Source | 0Source | -6,000Source | -84,000Source | 18,000Source | -197,000Source | -1,069,000Source |
| General and Administrative ExpenseUSD | — | — | 1,740,000Source | 2,747,000Source | 9,454,000Source | 1,956,000Source | 7,034,000Source | 1,921,000Source | 9,685,000Source | 10,499,000Source | 12,687,000Source | 13,001,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -205,929,000Source | -11,386,000Source | -8,142,000Source | -10,163,000Source |
| Interest Income (Expense), NetUSD | — | — | 42,000Source | 146,000Source | 4,059,000Source | 50,000Source | 3,070,000Source | 74,000Source | 1,167,000Source | 844,000Source | 1,689,000Source | 722,000Source |
| Nonoperating Income (Expense)USD | — | — | 23,000Source | -36,000Source | 4,075,000Source | -12,000Source | 3,070,000Source | 68,000Source | 1,083,000Source | 862,000Source | 1,556,000Source | -417,000Source |
| Operating ExpensesUSD | — | — | 3,156,000Source | 3,840,000Source | 34,994,000Source | 3,421,000Source | 30,811,000Source | 2,599,000Source | 210,872,000Source | 22,260,000Source | 39,905,000Source | 61,207,000Source |
| Research and Development ExpenseUSD | — | — | 1,416,000Source | 1,093,000Source | 25,540,000Source | 1,465,000Source | 23,777,000Source | 678,000Source | 26,877,000Source | 6,398,000Source | 23,770,000Source | 48,206,000Source |
| Restructuring CostsUSD | — | — | — | — | — | — | — | — | 0Source | 968,000Source | 3,448,000Source | — |
Offerings
Registration 333-292175
Registration 333-293343
Filing attachments
d135820dex42.htm · S-8 POS · 2026-08-10
Exhibit 4.2 DAMORA THERAPEUTICS, INC. 2026 EQUITY INCENTIVE PLAN Purpose ─────────── The purpose of this Damora Therapeutics, Inc. 2026 Equity Incentive Plan (the “Plan”) is to promote and closely align the interests of employees, officers, non-employee directors and other individual service providers of Damora Therapeutics, Inc. and its shareholders by providing share-based compensation and other performance-based compensation. The objectives of the Plan are to attract and retain the bes…
Read attachment ↗d135820dex43.htm · S-8 POS · 2026-08-10
Exhibit 4.3 DAMORA THERAPEUTICS, INC. 2026 EMPLOYEE STOCK PURCHASE PLAN Purpose ─────────── The purpose of this Damora Therapeutics, Inc. 2026 Employee Stock Purchase Plan (the “Plan”) is to provide employees of the Company and its Designated Subsidiaries with an opportunity to purchase Ordinary Shares through accumulated Contributions. The Company’s intention is to have the Plan qualify as an “employee stock purchase plan” under Section 423 of the Code. The provisions of the Plan, accord…
Read attachment ↗d135820dex44.htm · S-8 POS · 2026-08-10
Exhibit 4.4 DAMORA THERAPEUTICS, INC. 2025 EQUITY INCENTIVE PLAN Purpose. ──────────── The purpose of this 2025 Equity Incentive Plan (the “Plan”) of Damora Therapeutics, Inc., a Cayman Islands exempted company (the “Company”), is to advance the interests of the Company’s shareholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by providing such persons with equity ownership opportunities an…
Read attachment ↗d135820dex45.htm · S-8 POS · 2026-08-10
Exhibit 4.5 DAMORA THERAPEUTICS, INC. 2022 INDUCEMENT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Damora Therapeutics, Inc. 2022 Inducement Plan (the “Plan”). The purpose of the Plan is to enable Damora Therapeutics, Inc. (the “Company”) to grant equity awards to induce highly-qualified prospective officers and employees who are not currently employed by the Company and its Affiliates to accept employment and provide them with a proprietary interest i…
Read attachment ↗d135820dex46.htm · S-8 POS · 2026-08-10
Exhibit 4.6 DAMORA THERAPEUTICS, INC. 2020 STOCK OPTION AND GRANT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Damora Therapeutics, Inc. 2020 Stock Option and Grant Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, directors, Consultants and other key persons of Damora Therapeutics, Inc., a Cayman Islands exempted company (including any successor entity, the “Company”) and its Subsidiaries, upon whose judgme…
Read attachment ↗d135820dex47.htm · S-8 POS · 2026-08-10
Exhibit 4.7 DAMORA THERAPEUTICS, INC. 2020 EQUITY INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Damora Therapeutics, Inc. 2020 Equity Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable Employees, Non-Employee Directors and Consultants of Damora Therapeutics, Inc., a Cayman Islands exempted company (including any successor entity, the “Company”) and its Affiliates upon whose judgment, initiative and efforts the Comp…
Read attachment ↗